Natco Pharma appoints Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda

Published On 2025-06-17 06:28 GMT   |   Update On 2025-06-17 06:28 GMT
Advertisement

Telangana: Natco Pharma has appointed Yarramshetty Krishna Rao as Senior Vice President - Operations at Mekaguda of the Company.

Yarramshetty Krishna Rao has overall 33 years of experience in the leading Indian Bulk Drug/API Manufacturing Industries, with 20 years of experience as Unit Head. Prior to joining Natco, he served at Dr. Reddy’s Laboratories Limited, Hyderabad, as Senior Director/Site Head - API manufacturing unit.

Advertisement

This appointment follows a series of senior leadership changes Natco Pharma unveiled last month, effective from June 1, 2025. As part of its organizational strengthening across various verticals, the company named Dilip Manikchand Dhore as Vice President – Corporate Quality Assurance, and Amber Roy as Associate Vice President – Distribution.

Additionally, Addagada Veeranarayana and Parupalli Sreenivasa Rao were appointed Associate Vice Presidents – Operations, while Kurada Venkata Maruti Ramchander was designated as Associate Vice President – Regulatory Affairs.

Read also: Natco Pharma announces key leadership appointments across quality, operations, regulatory, and distribution teams

Earlier in April, Natco Pharma also announced the superannuation of two key executives: Dr. Ramesh Dandala, Executive Vice President – Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API), and Tummala Venkata Rao, Vice President – Production.

Read also: Natco Pharma Executive VP - Technology Transfer, Intellectual Property Rights & Regulatory Affairs (API), Dr Ramesh Dandala, superannuates

NATCO Pharma Limited, headquartered at Hyderabad, India, develops, manufactures and distributes generic and branded pharmaceuticals, specialty pharmaceuticals, active pharmaceutical ingredients and crop protection products. The Company is a R&D oriented, and a science driven, leading Oncology player in the targeted therapies of domestic market and focuses on limited competition molecule in the US. The Company has 9 manufacturing sites and 2 R&D facilities in India. The Company’s manufacturing facilities are approved by several leading regulatory authorities like US FDA, Brazil ANVISA, Health Canada, WHO and others catering to 50+ global markets.

Read also: Natco Pharma Tummala Venkata Rao supperannuates as Vice President - Production

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News